Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.
Multiple Myeloma (MM) is a common haematological condition primarily affecting older people, with a median age at diagnosis of about 65-70 years and a slight prevalence in male gender and in African-Americans. An abnormal plasma cell growth within the bone marrow accounts for this condition, leading to interference with normal haemopoiesis and excessive production of abnormal monoclonal antibodies (paraprotein). The activation of osteoclasts in the surrounding bone tissue exposes to the risk of pathological fractures and hypercalcemia.
Molecular imaging modalities such as fluorine-18- fluorodeoxyglucose positron emission tomography (FDG-PET) or positron emission tomography/computed tomography (FDG-PET/CT) have emerged recently as reliable methods in the initial staging and treatment planning of patients with MM. FDG is a glucose analogue which accumulates into cells in proportion with their glycolytic activity: therefore, high-metabolism neoplastic cells show an increased FDG uptake in comparison with normal surrounding tissue. Standardized Uptake Value (SUV) is a semi-quantitative estimate of glycolytic activity in neoplastic lesions.
Caldarella C, et al. Treglia G (2013) Treatment Response Monitoring in Patients with Multiple Myeloma: The Role of Positron Emission Tomography- Computed Tomography using Fluorine-18-Fluorodeoxyglucose. J Bone Marrow Res 1: e103. doi: 10.4172/2329-8820.1000e103
https://www.omicsonline.org/open-access/treatment-response-monitoring-in-patients-with-multiple-myeloma-the-role-of-positron-emission-tomography-computed-tomography-using-fluorine-18-fluorodeoxyglucose-jbmr.1000e103.php?aid=10498
Spanish 
Chinese 
Russian 
German 
French 
Japanese 
Portuguese 
Hindi